To ensure the promised ROI of generative AI—and mitigate risk—executives will need to expand the technology’s role within ...

AI in drug development is a vague term that might mean many things, and today, Owkin is announcing it has enrolled the first patient in a phase 1 study of OKN4395, its “AI-optimized” candidate for ...